Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

McGill University

$60,000.00

Targeting novel cancer-promoting pathways in breast cancer

FY 2018-19

Summary
Triple Negative Breast Cancer (TNBC) is one of the most lethal forms of breast cancer becase it is aggressive and difficult breast cancers to treat, due to a lack of specific drugs. TNBCs contain many mutations and other damage to their DNA, which, in theory, should make them susceptible for removal by the immune system. However, TNBCs can adapt to suppress the immune system, enabling the cancer to grow. Our lab studies a cancer promoting gene called aPKC. We identified that in some breast cancers aPKC can regulate a network that is known to suppress the immune system. In our project, we will evaluate how aPKC regulates cancer growth and whether it suppresses the immune system as part of its cancer promoting properties. There are clincailly available aPKC blocking drugs used to treat other diseases and in clinical trials for other cancer types. Our project will determine if aPKC inhibitors are a vaiable treatment option to consider for some TNBCs.
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
407424
Name
McCaffrey Luke M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Targeting novel cancer-promoting pathways in breast cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Breast Cancer
Abstract
Triple Negative Breast Cancer (TNBC) is one of the most lethal forms of breast cancer becase it is aggressive and difficult breast cancers to treat, due to a lack of specific drugs. TNBCs contain many mutations and other damage to their DNA, which, in theory, should make them susceptible for removal by the immune system. However, TNBCs can adapt to suppress the immune system, enabling the cancer to grow. Our lab studies a cancer promoting gene called aPKC. We identified that in some breast cancers aPKC can regulate a network that is known to suppress the immune system. In our project, we will evaluate how aPKC regulates cancer growth and whether it suppresses the immune system as part of its cancer promoting properties. There are clincailly available aPKC blocking drugs used to treat other diseases and in clinical trials for other cancer types. Our project will determine if aPKC inhibitors are a vaiable treatment option to consider for some TNBCs.
Competitiondate
201902
Approvedterm2
2 yrs 0 mth
Pinamesdelim
McCaffrey, Luke M
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~